Shares rose 6.9% following AbbVie’s first quarter, as revenues, EPS, and commercial performance in key franchises decisively beat expectations. Management announced an upward revision to full-year EPS guidance and highlighted strong execution across immunology and neuroscience portfolios. The positive market reaction suggests investors were focused on upside in top and bottom line performance, robust commercial momentum, and the confident guidance raise.

• Adjusted EPS for Q1 reached $2.65, $0.07 higher than the mid-point of previous guidance; full-year adjusted EPS guidance was raised by $0.12.
• Total net revenues came in at $15 billion, exceeding internal expectations by $300 million and representing 12.4% sales growth.
• Skyrizi sales jumped 29.2% operationally to $4.5 billion, with leadership in key dermatology and IBD indications, while Rinvoq sales rose 20.2% to $2.1 billion.
• Neuroscience revenues grew 24.3% operationally to nearly $2.9 billion, surpassing internal forecasts.
• Strategic investments were cited, including $1.4 billion for a new manufacturing campus in North Carolina and ongoing R&D pipeline advances across immunology, obesity, and oncology.